Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

GHRP-2

Pralmorelin, Growth Hormone Releasing Peptide-2, KP-102

A synthetic hexapeptide that mimics ghrelin to stimulate growth hormone release from the pituitary gland via GHS receptors.

Quick Stats
Studies 230
Trials 1
Formula C45H55N9O6
Clear All
Utility 3
pubmed Sep 1, 1995

Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature.

Tuilpakov. A N AN; Bulatov. A A AA; Peterkova. V A VA; Elizarova. G P GP; Volevodz. N N NN; Bowers....

In a small study of kids with short stature, a single IV dose of the peptide GHRP-2 raised growth hormone (GH) levels about as well as the natural hormone GHRH in children who were otherwise healthy, but it barely worked in kids who already had GH deficiency.

Utility 3
pubmed 1997

Growth hormone releasing peptides: a comparison of the growth hormone releasing activities of GHRP-2 and GHRP-6 in rat primary pituitary cells.

Cheng. J J; Wu. T J TJ; Butler. B B; Cheng. K K

The study shows that GHRP-2 triggers growth hormone release in rat pituitary cells just like GHRP-6, works best when paired with growth hormone‑releasing factor (GHRF), and doesn’t give extra benefit when both GHRP‑2 and GHRP‑6 are taken together. The two peptides can make each other less effective over time, but they don’t affect the response to GHRF.

Utility 3
pubmed 1998

A five day treatment with daily subcutaneous injections of growth hormone-releasing peptide-2 causes response attenuation and does not stimulate insulin-like growth factor-I secretion in healthy young men.

Nijland. E A EA; Strasburger. C J CJ; Popp-Snijders. C C; van der Wal. P S PS; van der Veen. E A EA

In a small study of nine healthy young men, daily injections of 100 ”g GHRP‑2 for five days kept releasing growth hormone, but the hormone spikes got smaller each day. After five days there was no rise in the blood level of IGF‑I (the downstream hormone linked to many anti‑aging claims), although a bone‑related marker called osteocalcin did go up.

Utility 3
pubmed 1997

The role of protein kinase C in GH secretion induced by GH-releasing factor and GH-releasing peptides in cultured ovine somatotrophs.

Wu. D D; Clarke. I J IJ; Chen. C C

In sheep pituitary cells, the growth‑hormone‑releasing peptide GHRP‑2 triggers GH release by activating both the PKC and the classic cAMP‑PKA pathways, and these two signaling routes help each other. Blocking PKC or PKA reduces the GH‑boosting effect of GHRP‑2, showing both are needed for full activity.

Utility 3
pubmed Sep 1, 1995

GH responses to intravenous bolus infusions of GH releasing hormone and GH releasing peptide 2 separately and in combination in adult volunteers.

Tiulpakov. A N AN; Brook. C G CG; Pringle. P J PJ; Peterkova. V A VA; Volevodz. N N NN; Bowers. C Y...

In a tiny study of eight healthy young men, a single IV dose of the peptide GHRP‑2 caused a much bigger spike in growth hormone (GH) than the natural hormone GHRH, and mixing the two didn’t make the effect any stronger than just adding their separate effects together.

Utility 3
pubmed Jul 26, 1996

Effects of the synthesized growth hormone releasing peptide, KP-102, on growth hormone release in sodium glutamate monohydrate-treated low growth rats.

Nakagawa. T T; Ukai. K K; Ohyama. T T; Koida. M M; Okamura. H H

In a rat study, the synthetic peptide KP-102 (a version of GHRP‑2) was able to boost growth hormone (GH) levels, even in rats that normally produce very little GH. The effect was strongest when the peptide was given directly into the brain or pituitary, but it still worked when injected into the bloodstream. However, the boost was much smaller than in normal rats, and the research was done only in anesthetized animals.

Utility 3
pubmed 1998

Intrahypothalamic perfusion of KP102 stimulates growth hormone release in goats.

Hashizume. T T; Sasaki. K K; Kobayashi. S S; Nitta. Y Y

In goats, directly delivering GHRP-2 into the brain’s hypothalamus caused a clear rise in growth hormone levels, showing that the peptide can act on the brain to boost GH release. This effect was seen without changing how often GH pulses occurred, but each pulse was larger. The study also showed that simply putting growth‑hormone‑releasing hormone (GHRH) into the hypothalamus didn’t work the same way, highlighting a unique action of GHRP‑2.

Utility 3
pubmed 1998

New GH secretagogues and potential usefulness in thalassemia.

Karydis. I I; Tolis. A A; Tolis. G G

The paper says that new growth‑hormone‑releasing drugs like GHRP‑2 can boost GH without injections, even when taken as a pill or nasal spray, and they seem safe. In thalassemia patients who have low GH despite a normal pituitary, these drugs give a stronger, longer‑lasting GH surge, making them a possible treatment.

Utility 3
pubmed 1997

Mechanisms of action of growth hormone-releasing peptide-2 in bovine pituitary cells.

Roh. S G SG; He. M L ML; Matsunaga. N N; Hidaka. S S; Hidari. H H

The study shows that GHRP‑2 directly triggers growth hormone release from cow pituitary cells and that its effect adds up with the natural hormone‑releasing factor (GHRF). The hormone boost depends on calcium entering the cells and involves protein‑kinase C and cAMP signaling pathways. Blocking calcium channels, the GHRF receptor, or adding somatostatin reduces the effect.

Utility 3
pubmed 2000

Growth hormone-releasing peptides and the cardiovascular system.

Muccioli. G G; Broglio. F F; Valetto. M R MR; Ghè. C C; Catapano. F F; Graziani. A A; Papotti....

Growth hormone‑releasing peptides (like GHRP‑2) don’t just boost GH – they also stick to heart tissue and can protect heart cells, improve heart pumping strength, and reduce damage from low‑oxygen events, even without involving GH.

Utility 3
pubmed Nov 21, 1995

Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

McDowell. R S RS; Elias. K A KA; Stanley. M S MS; Burdick. D J DJ; Burnier. J P JP; Chan. K S KS; Fa...

Scientists reshaped a growth‑hormone‑releasing peptide (GHRP‑2) to make it even smaller and more powerful. In lab tests and animal studies the new versions triggered strong GH release and helped build muscle when given intermittently. They also mapped the 3‑D shape of the best‑working version, giving clues for designing even better low‑weight secretagogues.

Utility 3
pubmed 1998

Human fetal pituitary expresses functional growth hormone-releasing peptide receptors.

Shimon. I I; Yan. X X; Melmed. S S

The study shows that the peptide GHRP-2 (and its sibling GHRP-6) can directly make human fetal pituitary cells release growth hormone, though it’s less powerful than the natural hormone GHRH. When both peptides are used together, they add up their effects but don’t boost each other beyond that. The peptide doesn’t change other hormones like ACTH or prolactin and can counteract the suppressive actions of IGF‑1 or somatostatin.

Utility 3
pubmed 1998

Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children.

Pihoker. C C; Kearns. G L GL; French. D D; Bowers. C Y CY

A small study gave kids with short stature a single tiny IV dose of GHRP‑2 and measured how the drug and growth hormone behaved in their blood. The peptide reliably boosted growth hormone levels, and the researchers worked out how fast it clears, how much spreads in the body, and the dose needed to get half‑maximal effect (EC50). This data can help design future dosing schedules, especially for non‑IV routes.

Utility 3
pubmed 2008

[Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD].

Arita. Kazunori K; Hirano. Hirofumi H; Tominaga. Atsushi A; Kurisu. Kaoru K

The paper explains that adult growth hormone deficiency (aGHD) often follows brain injuries like trauma or bleeding in the brain. It describes how a special test using the peptide GHRP‑2 can safely and quickly measure a person’s ability to release growth hormone, and it notes that growth‑hormone replacement can improve body composition, strength, and overall health in deficient patients.

Utility 3
pubmed 1996

The growth hormone-releasing peptide KP-102 induces c-fos expression in the arcuate nucleus.

Kamegai. J J; Hasegawa. O O; Minami. S S; Sugihara. H H; Wakabayashi. I I

A new version of the growth‑hormone‑releasing peptide (KP‑102, similar to GHRP‑2) was shown to activate specific brain cells in the arcuate nucleus that are known to make growth‑hormone‑releasing factor (GRF). This suggests the peptide works partly by stimulating the brain, not just the pituitary gland.

Utility 3
pubmed 1995

Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature.

Pihoker. C C; Middleton. R R; Reynolds. G A GA; Bowers. C Y CY; Badger. T M TM

The study shows that GHRP‑2, given either by IV or as a nasal spray, reliably triggers a strong growth‑hormone surge in children with short stature—about the same as the classic hormone GHRH. A nasal dose of 5‑20 ”g per kg (≈15 ”g/kg gave the biggest average spike) worked well and was well tolerated, and mixing GHRP‑2 with GHRH gave an even bigger, synergistic response.

Utility 3
pubmed 1998

Specific receptors for synthetic GH secretagogues in the human brain and pituitary gland.

Muccioli. G G; Ghè. C C; Ghigo. M C MC; Papotti. M M; Arvat. E E; Boghen. M F MF; Nilsson. M H...

The study shows that synthetic growth‑hormone secretagogues like GHRP‑2 bind to specific high‑affinity receptors in the human pituitary and several brain areas, especially the hypothalamus. This suggests these peptides can act directly in the brain, not just on the pituitary, and may influence GH release and possibly other brain functions.

Utility 3
pubmed Sep 10, 1998

A new series of highly potent growth hormone-releasing peptides derived from ipamorelin.

Ankersen. M M; Johansen. N L NL; Madsen. K K; Hansen. B S BS; Raun. K K; Nielsen. K K KK; Thogersen....

Scientists made new versions of the growth‑hormone‑releasing peptide ipamorelin that can be taken by mouth. One of them, called NNC 26‑0235, works as well as the classic GHRP‑2/6 in animals and shows about 10% oral bioavailability, meaning a small but measurable amount gets into the bloodstream when you swallow it.

Utility 3
pubmed Oct 9, 1998

The growth hormone secretagogue KP-102-induced stimulation of food intake is modified by fasting, restraint stress, and somatostatin in rats.

Shibasaki. T T; Yamauchi. N N; Takeuchi. K K; Ishii. S S; Sugihara. H H; Wakabayashi. I I

In rats, the growth hormone secretagogue KP-102 (similar to GHRP‑2) makes animals eat more, but only when they are already fed. If the rats have been fasting for a day, the drug doesn't boost eating. Stress reduces food intake, yet giving KP-102 directly into the brain can partly reverse that drop. Adding somatostatin (a hormone that blocks growth hormone) weakens KP-102's appetite‑boosting effect, though somatostatin alone doesn't change eating.